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Abstract
Background: Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive
regulatory T-cells (TRegs) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Ra/CD25) can enhance anti-
tumor immunotherapy. However, therapeutic approaches are complicated by the inadvertent inhibition of IL-2Ra
expressing anti-tumor effector T-cells.
Objective: To determine if changes in the cytokine milieu during lymphopenia may engender differential signaling
requirements that would enable unarmed anti-IL-2Ra monoclonal antibody (MAbs) to selectively deplete TRegs while
permitting vaccine-stimulated immune responses.
Methodology: A randomized placebo-controlled pilot study was undertaken to examine the ability of the anti-IL-2Ra MAb
daclizumab, given at the time of epidermal growth factor receptor variant III (EGFRvIII) targeted peptide vaccination, to
safely and selectively deplete TRegs in patients with glioblastoma (GBM) treated with lymphodepleting temozolomide (TMZ).
Results and Conclusions: Daclizumab treatment (n=3) was well-tolerated with no symptoms of autoimmune toxicity and
resulted in a significant reduction in the frequency of circulating CD4+Foxp3+ TRegs in comparison to saline controls (n=3)(
p=0.0464). A significant (p,0.0001) inverse correlation between the frequency of TRegs and the level of EGFRvIII specific
humoral responses suggests the depletion of TRegs may be linked to increased vaccine-stimulated humoral immunity.
These data suggest this approach deserves further study.
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Introduction
CD4
+CD25
+Foxp3
+ regulatory T-cells (TRegs) are an immuno-
suppressive lymphocyte subset comprising 5–10% of the CD4
+
compartment in both mice and humans [1]. TRegs potently inhibit
T-cell cytokine secretion and proliferation [2–6], directly curtail
the generation and expansion of endogenous or induced immune
responses [7–16], and appear to play a significant role in hindering
immunity to normal and tumor-associated antigens [17,18].
Increased levels of TRegs have been found in the tumors and
peripheral blood of patients with various malignancies including
glioblastoma multiforme (GBM), and within GBM, we have shown
TRegs to be an important and reversible component of the
immunosuppression endemic to this disease [19–23].Early at-
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immunosuppression targeted the high affinity interleukin-2 (IL-2)
Receptor (IL-2Ra/CD25) due to its constitutive expression on the
TReg population. Denileukin diftitox, a fusion protein of IL-2 and
a portion of the diphtheria toxin, and LMB-2, a fusion protein of
an anti-IL-2Ra MAb and a portion of a bacterial exotoxin, have
been utilized in humans to deplete TRegs but have achieved
inconsistent successes in improving immunotherapy [24–27];
potentially because activated effector T-cells transiently express
IL-2Ra [28]. Unarmed anti-IL-2Ra antibodies that block IL-2
signaling [29], as opposed to cytolytic targeted therapies, have the
potential to act differentially upon T-cells depending on their
requirement for IL-2. Additionally, work from our laboratory [30]
and others [31] has shown in murine models that anti-IL-2Ra
MAbs can deactivate TReg suppression through functional
inhibition as well as depletion.
A recent report by Jacobs et al. [32] examined the ability of the
humanized anti-IL-2Ra MAb daclizumab to deplete TRegs in
metastatic melanoma patients receiving antitumor vaccination in
the absence of chemotherapy. They demonstrated that while TRegs
were effectively depleted, the functionality of vaccine-induced anti-
tumor T-cells was impaired and the formation of vaccine-induced
humoral immunity was blocked; suggesting that daclizumab will
impair both TRegs and effector T-cell activation. However,
administration of anti-IL-2Ra MAb during lymphopenia may
function differently than in a normal non-lymphopenic context
due to disparate IL-2 signaling requirements by regulatory versus
effector T-cells. Preclinical studies in our lab corroborate this
hypothesis as anti-IL-2Ra MAb administration during temozolo-
mide (TMZ) induced lymphopenia depletes TRegs while sparing
activated effectors to enhance anti-tumor efficacy in an established
model of murine tumorigenesis [33]. Therefore, we believe that
the application of anti-IL-2Ra MAbs during standard chemother-
apy-induced lymphopenia in patients with cancer will selectively
ablate or inactivate TRegs while permitting immune responses
induced by anti-tumor immunotherapy.
We herein report that a single dose of the anti-IL-2Ra MAb
daclizumab, given concomitant with epidermal growth factor
receptor variant III (EGFRvIII) targeted vaccination in a
randomized saline-controlled pilot study, has the capacity to safely
and effectively deplete CD4
+Foxp3
+ TRegs in TMZ-treated
patients with GBM without impairing vaccine-induced immune
responses (Figure 1). EGFRvIII is a tumor-specific mutation
commonly found on GBMs [34] as well as breast, lung, head and
neck cancers [35–37] and studies from our group demonstrate that
peptide vaccination targeting the mutant fusion junction of
EGFRvIII prolongs survival time in a selected population of
patients with GBM treated in multi-institutional Phase II trials
[38–40]. Daclizumab given concomitantly with EGFRvIII-target-
ed vaccination significantly depleted TRegs (p=0.0464) without
impairing EGFRvIII specific antibody titers. Additionally, vac-
cine-stimulated anti-EGFRvIII antibody levels showed a signifi-
cant inverse correlation with the frequency of TRegs (r=20.93,
p,0.0001). The cumulative data suggests that administration of
an anti-IL-2Ra MAb during lymphopenia is not only safe, but that
it notably reduces TRegs allowing enhanced vaccine-stimulated
immunity.
Results
In vitro impact of daclizumab on effector T-cell function
Daclizumab is a humanized MAb that specifically binds to the
high affinity IL-2 receptor and blocks IL-2 binding [41]. IL-2Ra
inhibition mediated by daclizumab has been shown to inconsis-
tently inhibit T-cell function in vitro [29,42]. To begin assessing the
functionality of CD4
+ and CD8
+ effector T-cells exposed to anti-
IL-2Ra MAbs, we performed a two week in vitro activation with
dendritic cells (DCs) expressing the immunodominant Cytomegalo-
virus (CMV) pp65 protein, a model human antigen, in the presence
of increasing concentrations of daclizumab (Figure 2A & 2B). As a
marker of functionality, T-cells were examined for the secretion of
interferon-gamma (IFN-c) after stimulation with the superantigen
SEB or restimulation with CMV pp65 peptide mix. The secretion
of IFNc by CD4
+ T-cells stimulated with CMV or SEB was
enhanced by increasing doses of daclizumab. While increasing
doses of daclizumab diminished IFN-c secretion by CD8
+ T-cells;
IFN-c secretion could be rescued in the presence of interleukin 15
(IL-15). Importantly, IL-15 bioavailability is increased during
lymphopenia induced homeostatic proliferation [43] and our in
vitro data in combination with other preclinical studies from our
laboratory supports the possibility that daclizumab may well
function differentially on effector T-cells and TRegs in vivo during
TMZ induced lymphopenia.
Clinical Trial
To begin assessing the potential of a single dose of
daclizumab, a clinically-approved aIL-2Ra MAb, to reduce or
eliminate TRegs in lymphopenic patients with newly-diagnosed
GBM undergoing standard-of-care TMZ therapy (Zenapax-
Activated Peptide ImmunoTherapy (ZAP IT) Protocol - FDA -
IND - BB - 9949, Duke IRB Pro00000947); six patients with
EGFRvIII-expressing GBM were treated with standard of care
radiation with TMZ therapy and then randomized in a double-
blinded fashion to saline (n=3) or daclizumab (n=3). With an
original accrual goal of 20 patients, enrollment on this trial was
halted after six patients due to discontinuation of the availability
of daclizumab by the manufacturer. Patients began the first cycle
of 200 mg/m
2 T M Zf o r5d a y sa n do nd a y2 1 62c o n c o m i t a n t l y
received the PEPvIII peptide EGFRvIII-targeted vaccine [39]
and a single infusion of daclizumab (1 mg/kg) or saline.
Extensive work from our laboratory has shown that PEPvIII
peptide vaccination elicits potent and predominantly humoral
responses generating high levels of anti-PEPvIII specific
antibodies [38–40]. Patient characteristics and a schematic of
the ZAP IT study are summarized in Table 1 and Figure 3
respectively. All enrolled patients, were randomized and
included in the study analysis.
A single infusion of daclizumab in the context of
immunization is safe
Given that this trial may be establishing new treatment
regimens with the potential for an increased risk of toxicity,
patients were clinically assessed before each vaccination and a
panel of clinical laboratory analyses were additionally performed
to screen for the most common manifestations of autoimmunity
seen in related trials [44–47]. Daclizumab administration in the
context of EGFRvIII-targeted immunization was well-tolerated
with no adverse events beyond itching, swelling and redness at
the vaccination site attributable to the vaccine and no changes in
autoimmune laboratory analyses relative to baseline in daclizu-
mab or saline treated individuals. For each patient, the average
percent change between baseline (i.e. vaccine 1) and vaccine 4,
5, and 6 time points was computed for cortisol, TSH and
ACTH. A two-sample t-test comparison of the daclizumab and
saline groups with respect to these outcomes demonstrated no
evidence of a difference (p=0.4229, p=0.5653, p=0.3795,
respectively).
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the effector T-cell to TReg Ratio
The frequency of patient CD4
+, CD8
+ and CD4
+Foxp3
+
regulatory T-cells were monitored by complete blood counts
(CBC) and flow cytometric analysis over the course of treatment.
Throughout this study, TRegs were defined as CD4
+Foxp3
+ as
opposed to CD4
+CD25
+Foxp3
+ as the binding of daclizumab to
CD25 can impair the antibody-mediated flow cytometric detection
of CD25 and may lead to subjectivity in determining the TReg
population. For each patient, the average percent change in the
frequency of CD4
+Foxp3
+ regulatory T-cells between baseline and
the vaccine 2, 3 and leukapheresis time points was calculated. A
two-sample t-test comparison showed that a single infusion of
daclizumab resulted in a significant reduction in circulating TRegs
(p=0.0464; Figure 4). For the observed time-points, TRegs reached
a nadir approximately one month after daclizumab administration
and had not returned to baseline levels by vaccine 6 (day 11262).
The impact of daclizumab on the percent change in the frequency
of CD8
+ and overall CD4
+ T-cells was also examined and showed
considerable inter-patient variability, demonstrating no average
trend in either direction as opposed to the notable decrease that
was seen in the TReg population after infusion with daclizumab.
Therefore, daclizumab administration significantly reduces TRegs
in TMZ treated patients with GBM with no evidence of a
corresponding depletion of CD4
+ or CD8
+ T-cells.
To determine if daclizumab had any impact on the proliferative
capacity of effector T-cells or TRegs, cells were analyzed for Ki67
status by flow cytometric analysis at baseline, leukapheresis and
vaccine 4 time-points. No difference in the average percent change
from baseline to leukapheresis and vaccine 4 between the
daclizumab and saline groups with respect to CD4
+ and CD8
+
T-cells was detected (p=0.4947 and p=0.8113, respectively),
suggesting that unarmed MAb blockade of IL-2Ra may not impair
effector T-cell expansion. Though not statistically significant, there
is a trend towards the daclizumab group having a smaller percent
reduction in the average percent change from baseline in the
Figure 1. CONSORT 2010 Flow Diagram. Flow diagram of enrollment, allocation, follow-up and analysis of the ZenapaxH Activated Peptide
Immunotherapy (ZAP IT) Clinical Trial.
doi:10.1371/journal.pone.0031046.g001
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+TRegs relative to the saline group (p=0.0841).
This may simply be indicative of the regenerating TReg population
rebounding in response to daclizumab-mediated depletion
[48,49].
As anti-IL-2Ra MAb administration has been shown to
suppress vaccine-induced immunity [28,32], the activation status
of CD4
+ T-cells was also assessed by examining HLA-DR
expression. No difference in HLA-DR expression on CD4
+ T-
cells in daclizumab treated patients relative to controls was found
(p=0.4861); suggesting that daclizumab may not impair CD4
+
effector T-cell activation.
Preclinical and clinical studies show that increased systemic and
intratumoral ratios of effector T-cells to TRegs are associated with
favorable cancer prognoses and enhanced anti-tumor efficacy after
immunotherapy [50–54]. To assess the impact of daclizumab
treatment on the ratio of CD4
+ and CD8
+ effector T-cells to TRegs,
the absolute number of T-cells was divided by the absolute
number of TRegs and this ratio was compared to the ratio at
baseline (Figure 5). A two sample t-test of this outcome averaged
over the V-2, V-3 and LP time-points was generated to assess any
statistical difference between daclizumab and saline treated
patients. Both the CD4
+:TReg and the CD8
+:TReg ratios were
notably altered in the arm receiving daclizumab as compared to
saline controls with the ratio of CD4
+:TRegs trending towards
significance and the ratio of CD8
+:TRegs demonstrating a
significant increase in the average percent change from baseline
(p=0.0757 and p=0.0153, respectively). The enhancement of
effector to TReg ratios after daclizumab infusion suggests that
daclizumab administration in TMZ treated patients with GBM
may create an environment conducive to immunotherapeutic
intervention. In contrast to preclinical [28] and clinical studies
[32] examining MAb mediated inhibition of IL-2Ra in non-
lymphopenic individuals, our cumulative data suggests that in
TMZ treated patients with GBM, a single infusion of daclizumab
effectively depletes TRegs without notably impacting the CD4
+ or
CD8
+ effector T-cell compartments.
Figure 2. In vitro effects of IL2Ra inhibition on CD4
+, CD8
+ and regulatory T-cells. Normal donor peripheral blood mononuclear cells
(PBMCs) were cultured for 48 hours with increasing concentrations of daclizumab followed by an additional 14 days stimulation/expansion with CMV
pp65 RNA-pulsed DCs along with IL-2 or IL-15. PBMC were then isolated and stimulated for 6 hours with SEB or pp65 peptide mix in the presence of
CD28/CD49d costimulation and Brefeldin A. The IFN-c secretion of (A) CD3
+CD4
+CD69
+ or (B) CD3
+CD8
+CD69
+ T-cells was determined by flow
cytometry.
doi:10.1371/journal.pone.0031046.g002
Table 1. ZAP IT Patient Characteristics.
Patient Treatment Gender Age EGFRvIII Intensity (+ to 3+) TMZ Cycles KPS
1 Daclizumab F 64 3+ 12 100
2 Daclizumab M 78 3+ 12 80
3 Saline M 50 2–3+ .12 100
4 Saline M 60 3+ 12 90
5 Daclizumab M 55 2+ 12 90
6 Saline F 35 2+ 39 0
. As of the lock date of the data, the indicated patient had 12 cycles of TMZ but continued with additional cycles of TMZ treatment.
doi:10.1371/journal.pone.0031046.t001
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Regulatory CD56
Bright natural killer (NK) cells have been
shown to both be expanded by the addition of daclizumab and to
indirectly mediate the inhibitory effects of aIL-2Ra MAbs on
effector T-cells [42,55]. For each patient, the average percent
change between baseline, leukapheresis and vaccine 4 time
points was computed for the frequency of regulatory
CD3
2CD56
BrightCX3CR1
2 NK cells. No difference between
daclizumab and saline groups was detected (two sample t-test
p=0.7088). It is possible that in this lymphodepleted context,
daclizumab expanded regulatory NK cells that might normally
impair effector T-cells are not present and therefore anti-IL-2Ra
MAbs would generate a selective impairment on the TRegs
population.
Daclizumab remains bound to residual TRegs
The half-life of daclizumab is 20 days [56] and it has been
indirectly shown that daclizumab can remain bound to TRegs for
weeks after administration [42,57]. To determine if daclizumab
remains bound to residual TRegs in TMZ treated patients with
GBM, TRegs were isolated both before and after saline or
daclizumab administration and identical samples were separately
stained for the frequency of CD4
+CD25
+Foxp3
+ TRegs with an
anti-CD25 antibody that recognizes the Tac epitope (competing
with daclizumab, clone 2A3) and one that does not (non-
competing, clone MA251). The ratio of TRegs (non-competing
antibody/competing antibody) was determined and a ratio greater
than 1 indicates a TReg population that is only detectable by the
non-competing antibody. This demonstrates that detection of
TRegs by the competing antibody is blocked by the presence of
daclizumab bound to IL-2Ra. The percent change in this ratio
from baseline (vaccine 1) to leukapheresis (35 days after
daclizumab) was used to determine the amount of daclizumab
remaining bound to the TRegs. An increase in percent change
indicates an increase in the ratio from baseline, demonstrating that
35 days after daclizumab administration there is a population of
TRegs detectable only by the non-competing antibody as
daclizumab bound to IL-2Ra prevents binding of the competing
antibody (Figure 6A). Additionally, to determine if the presence of
daclizumab on TRegs could be directly visualized, TRegs were
stained with a goat anti-human antibody and the presence of
human antibody was detected on TRegs exclusively in the
daclizumab treated patient (Figure 6B). These results indicate
that daclizumab remains bound to a population of residual TRegs
persisting after depletion.
The frequency of TRegs is inversely correlated with
vaccine-stimulated humoral responses
Numerous preclinical studies have demonstrated that anti-IL-
2Ra MAb administration can deplete or functionally inactivate
TRegs in mice and can augment anti-tumor immunotherapy if
delivered as a prophylactic prior to vaccination [30,50,58].
However, if delivered therapeutically in these models, anti-IL-
2Ra MAbs have been shown to impair anti-tumor immune
responses potentially due to inhibition of the activated effector T-
cells expressing CD25 [28]. Daclizumab administration in non-
lymphopenic metastatic melanoma patients significantly depletes
TRegs but additionally impaired vaccine-induced anti-tumor T-cell
function and prevented vaccine-induced humoral immunity [32].
We have previously demonstrated that the PEPvIII peptide
vaccine mediates efficacy through a humoral biased immune
response [39] and we examined patients in this study for
alterations in humoral immunity. As opposed to the findings of
Jacobs et al., no reduction in anti-PEPvIII antibody titers was
detected between daclizumab and saline treated patients, indicat-
ing daclizumab does not block vaccine-induced humoral immunity
in TMZ treated patients with GBM. To examine the potential
Figure 4. Regulatory T-cells are significantly depleted by a
single infusion of daclizumab. The frequency of CD4
+Foxp3
+ TRegs
was determined by FACS analysis of peripheral blood samples drawn
prior to vaccination (V) or leukapheresis (LP). Percent change was
calculated in comparison to baseline (vaccine 1). For each follow-up
assessment, percent change from baseline (vaccine 1) was computed.
For statistical comparisons of the daclizumab and saline groups, the
average percent change at vaccine 2 (V-2), vaccine 3 (V-3), and
leukapheresis (LP) was computed for each patient. Daclizumab showed
a significantly greater reduction in CD4
+Foxp3
+ regulatory T-cells
(p=0.0464).
doi:10.1371/journal.pone.0031046.g004
Figure 3. Schema of ZAP IT Trial.
doi:10.1371/journal.pone.0031046.g003
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induction of vaccine-induced antibody responses, we plotted the
frequency of TRegs against anti-PEPvIII antibody titers from both
saline and daclizumab patients (Figure 7). While our analysis does
not demonstrate causality, there was a significant (p,0.0001)
inverse correlation (r=20.93) between the frequency of TRegs and
the concentration of anti-PEPvIII antibody, suggesting that high
TReg levels are associated with low anti-PEPvIII antibody
responses and low TReg levels are associated with increased anti-
PEPvIII antibody responses. As our cumulative data demonstrates
that a single infusion of daclizumab is a safe and effective means of
sustained TReg depletion, this method may be used to reduce TRegs
for the augmentation of vaccine-induced immunity as suggested by
our heightened anti-PEPvIII antibody titers.
Figure 5. In vivo effects of daclizumab on the effector T-cell to regulatory T-cell ratio. (A–B) Effector T-cells (CD4
+ or CD8
+)t oT Reg ratios
were derived by dividing the absolute number of effector T-cells by the absolute number of TRegs at the indicated time-points; the absolute number
of cells was determined by a combination of CBC and FACS analysis. The ratios of effector T-cells to TRegs as compared to baseline were generated by
dividing the individual patient CD4
+:TReg or CD8
+:TReg ratio at every time point by the ratio at vaccine 1 (V-1=baseline). A two sample t-test averaged
over the V-2, V-3 and LP time-points was utilized to examine the difference between the daclizumab and saline groups in the CD4
+:TReg (p=0.0757)
and CD8
+:TReg (p=0.0153) ratios.
doi:10.1371/journal.pone.0031046.g005
Figure 6. Daclizumab remains bound to TRegs a month after administration. (A) CD4
+Foxp3
+ TRegs from day 3562 leukapheresis samples
(saline n=3, daclizumab n=3) were determined by flow cytometry and were additionally stained with anti-CD25 antibodies that bind the same CD25
eptiope as daclizumab (competing clone 2A3) or bind a separate epitope (non-competing clone MA251). The ratio of the frequency of
CD4
+CD25
+Foxp3
+ TRegs as determined by MA251 or 2A3 binding was used as an indirect indicator of surface daclizumab expression. The percent
change in the ratio was calculated from ratios determined from baseline (vaccine 1) samples, unpaired t-test *p=0.0353. (B) CD4
+CD25
+Foxp3
+ TRegs
were determined by FACS analysis of PBMC and examined for human antibody expression as a direct indicator of daclizumab binding to the surface
of TRegs. PBMCs from a saline and a daclizumab treated patient from vaccine 1 (Pre-Daclizumab) and leukapheresis at day 3562 (Post-Daclizumab)
time-points were assessed.
doi:10.1371/journal.pone.0031046.g006
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The results presented herein demonstrate that the unarmed IL-
2Ra-specific antibody daclizumab effectively eliminates TRegs in
TMZ treated patients with GBM without decreasing effector T-cell
populations or impairing vaccine-stimulated immunity. In vitro,
these antibodies enhance IFN-c production to an antigen-specific
andnonspecificstimulusinCD4
+T-cells,andwhileIFN-c secretion
by CD8
+ T-cells was blunted, this was rescued with the addition of
IL-15, a homeostatic cytokine that would be present in patients
recovering from chemotherapy-induced lymphopenia. This sup-
ports our hypothesis that IL-2Ra-specific antibodies may have
differential effects on TRegs and anti-tumor effector T-cells in the
milieu of homeostatic cytokines which would be seen in patients
treated with lymphodepleting chemotherapies, such as TMZ, which
is now standard-of-care for patients with GBM. Enrollment on this
study was halted due to unanticipated discontinuation of the
availability of daclizumab by the manufacturer. However, when
assessed in our randomized saline-controlled pilot study ‘‘ZAP-IT’’,
daclizumab administration was safe, depleted TRegs, did not deplete
CD4
+ or CD8
+ effector T-cells and increased the ratio of CD4
+ and
CD8
+ effectors to TRegs. Importantly, decreased TReg numbers
strongly correlated with heightened vaccine-induced humoral
responses, suggesting TReg depletion may augment vaccine-induced
humoral immunity. Finally, unlike other approaches to enhancing
immune response in cancer patients [44–47], we saw no evidence of
toxicity despite the dramatic reduction in regulatory T-cell numbers
that we observed.
Other TReg depletion strategies, such as the IL-2 targeted toxins
denileukin diftitox and LMB-2, have been used in clinical studies
and have had partial success in the in vivo reduction of regulatory
T-cells [24–26,59,60]. However, these strategies have limitations
not found when using unarmed MAb blockade. Denileukin
diftitox targets the IL-2 moiety itself allowing indiscriminate
targeting of the lower affinity IL-2ßc receptors which are
expressed on a broader subset of cells including memory T-cells.
Thus, denileukin diftitox cannot distinguish between TRegs and
activated and memory T-cells expressing any of the IL-2 receptors
and may even stimulate TRegs. Alternative strategies that employ
IL-2Ra-targeted immunotoxins, such as LMB-2, still allow
indiscriminate killing of all IL-2Ra-expressing cells including
recently activated, vaccine-induced effector T-cells that express IL-
2Ra.
We and others have recently shown, however, that unarmed
anti-IL-2Ra antibodies may function differently and not have a
direct cytotoxic effect [30,31]. Rather, these antibodies may
impair regulatory T-cells by blocking IL-2 receptor signaling
through their cognate receptor. TRegs are known to be uniquely
dependent on the high affinity IL-2 receptor for their function and
survival [61–64] and MAbs that block IL-2Ra have been shown to
significantly reduce regulatory T-cell activity in preclinical models
[30,65–67]. While these antibodies would also bind IL-2Ra on
activated T-cells, activated effectors may not require this signaling,
as others have demonstrated that IL-2 signals during priming are
required for robust secondary memory T-cell responses and that
activated T-cells are not dependent on IL-2 signaling during the
primary response [68]. It is additionally quite conceivable that by
the time patients are diagnosed and treated, that most tumor
antigens actually represent memory T-cells which would not be
dependent on IL-2 signaling to generate secondary immune
Figure 7. The frequency of TRegs and anti-PEPvIII humoral responses are inversely correlated. Patient sera from peripheral blood (vaccine
4) and leukapheresis samples were analyzed for levels of anti-PEPvIII antibodies and humoral responses were plotted against the frequency of TRegs
(Foxp3
+ of CD4
+). Assuming the assessments within individuals are independent, the Spearman correlation coefficient for both saline and daclizumab
treated patients overall is (R=20.93, p,0.0001).
doi:10.1371/journal.pone.0031046.g007
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IL-15, that are prevalent during lymphopenia, have been shown to
be able to substitute for IL-2 signaling in activated effector cells
[43]. Thus, when anti-IL-2Ra MAbs are employed in the unique
host environment that exists after therapeutic TMZ-induced
lymphodepletion, vaccine-stimulated anti-tumor T-cells may be
independent of IL-2 signaling whereas TRegs will remain
dependent. This differential effect should lead to increased
effector:TReg ratios as we have seen here, but remains wholly
dependent on a lymphodepleted environment. Given the prior
difficulties in eliminating TRegs without impairing T-cell effectors,
it has been controversial whether or not the depletion of TRegs
would enhance immune responses. Our data demonstrating the
inverse correlation between TReg frequency and vaccine-stimulat-
ed antibody levels suggests that reducing TRegs may improve
vaccine-induced immunity and warrants further investigation. Of
note, TReg depletion using daclizumab was incomplete in these
patients using a single intravenous administration, suggesting
either incomplete saturation of IL-2Ra receptors at the dose used
(1 mg/kg), downregulation or shedding of IL-2Ra from the
surface of TRegs that renders some cells refractory to an antibody
dependent elimination, or a refractory population of FOXP3+
CD4+ TRegs that is not amenable to elimination by anti-IL-2Ra
MAbs treatment. We did not differentiate in this study, for
instance, whether thymic-derived natural TRegs, (nTRegs) versus
peripherally converted TRegs are preferentially depleted by anti-
IL-2Ra blockade. This is of importance since, recent studies have
demonstrated that thymic-derived TRegs predominate in patients
with malignant brain tumors [69]. The early and significant
depletion of TRegs shortly after antibody administration in patients
after surgical resection, suggests that n TRegs are likely effectively
depleted by this treatment but determination of the effects of anti-
IL-2Ra MAbs on TReg subsets constitute an important area for
future research.
The results of our trial examining the impact of daclizumab and
anti-tumor vaccination differ widely from the recent work of
Jacobs et al. [32] in which the administration of daclizumab
successfully depleted TRegs but impaired vaccine-stimulated T-cell
function and prevented antibody formation. In our study, robust
PEPvIII-specific humoral responses were present in both the saline
and daclizumab arms and the presence of class-switching indicates
that functional CD4
+ T-cell help must have been provided.
Additionally, our study demonstrates that lower TReg levels
actually correlate with improved anti-PEPvIII antibody responses.
Key differences between our study and the work of Jacobs et al.
include type of vaccination (peptide versus DC), randomization
(randomized versus not randomized) as well as administration and
dose of daclizumab (1 mg/kg at vaccination versus 0.5 mg/kg 4 or
8 days prior to vaccination). However, we believe the fundamental
difference is that our application of daclizumab and anti-tumor
vaccination occurs in the context of lymphopenia and it is this
setting that permits daclizumab to selectively deplete TRegs while
leaving vaccine-stimulated anti-tumor immunity intact.
Although promising, our study does have a number of
limitations, one of which is despite being randomized, blinded
and placebo-controlled; the number of patients enrolled in this
trial is small due to discontinuation of the availability of
daclizumab. However, these results have been reproduced in
two separate phase I trials we have conducted more recently. In
the first trial, patients were vaccinated against Cytomegalovirus,
pp65, a tumor antigen now known to be specifically expressed in
GBM [70–73]. While patients treated with vaccine alone have a
median progression free survival of only 15.4 months, patients in
the second study [33] treated with a combination of vaccination
and concomitant daclizumab have a progression-free survival of
27.2 months. While these are also small studies, these results may
be significant given that the expected progression-free survival is
6.9–8.2 months in this patient population [74,75]. While the
EGFRvIII-specific vaccine has been previously shown to stimulate
predominantly humoral responses, in these other trials we are
additionally examining differences in T-cell responses. The results
of our cumulative data provide a safe, novel and much needed
method for depleting TRegs without impairing activated effector T-
cells. Unfortunately, the discontinuation of the availability of
daclizumab precluded further study of the effects of this drug on
immunologic responses. A chimeric monoclonal antibody targeted
CD25, basiliximab, however is currently available and studies
evaluating the use of this antibody to selectively deplete TRegs are
underway. The utility of repeated administration of anti-IL-2Ra
MAbs during recovery from lymphopenia and the effects of dose-
escalation of TMZ to achieve greater and sustained lymphopenia
constitute potential avenues for exploitation of the use of anti-IL-
2Ra MAbs in cancer immunotherapy.
Materials and Methods
Patient Selection, Clinical Protocol and Ethics Statement
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. Adults with a first time histopathologic diagnosis of
GBM (WHO Grade IV) and a Karnofsky Performance Scale
(KPS) score $80 were eligible for vaccination if tumor cells
expressed EGFRvIII by Immunohistochemistry (IHC), and they
had no radiographic evidence of progression after radiation
therapy. The trial design and written Informed Consent were
approved by the U.S. Food and Drug Administration (under BB-
IND-9,944) and the local Institutional Review Board at Duke
University (00000947). Prior to the first vaccine the patients were
randomized to receive daclizumab or saline. The original study
was designed for enrollment of twenty patients but was halted after
enrollment of six patients due to discontinuation of the drug
daclizumab by the manufacturer (Roche).
Vaccine Product and Administration
The vaccine consisted of a 13-amino-acid peptide that spans the
EGFRvIII mutation (LEEKKGNYVVTDHC) conjugated to
keyhole limpet hemocyanin (KLH) and was manufactured by
Celldex, CDX-110/rindopepimut. The CDX-110/rindopepimut
(500 mg/immunization) was mixed with granulocyte-macrophage
colony-stimulating factor (GM-CSF) (150 mg/immunization) with-
in 30 minutes of administration. All vaccines were given
intradermally within 10 cm of the inguinal ligament on alternating
sides on day 2162 of each 28 day TMZ cycle.
Flow cytometric analysis of PBMC
PBMC were potentially stained for the following surface
antigens: CD4-FITC (clone RPA-T4; BD, San Diego, CA), CD8
(clone RPA-T8; BD Bioscience, San Diego, CA), CD25-PE (clone
MA251 or clone 2A3; BD Bioscience, San Diego, CA), CD127-
PerCpP-Cy5.5 (clone hIL-7R-M21; BD Bioscience , San Diego,
CA) or goat anti-human-PE (#109-486-127, F(ab9)2 fragment;
Jackson Immuno Research, West Grove, PA). Cells were washed
extensively and incubated on ice for 30 minutes in fixation/
permeabilization buffer (eBioscience, Cat # 00-5123-43, San
Diego, CA). For TReg analysis, after surface staining cells were
washed in 16 permeabilization buffer (eBioscience, Cat # 00-
8333-56, San Diego, CA), pelleted, and stained with Foxp3-APC
(clone PCH101; eBioscience, San Diego, CA). Samples were
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with FlowJo (TreeStar, Ashland, OR).
In vitro analysis of PBMC
PBMC from normal donors were incubated for 48 hours in
AIM-V media (Gibco, Cat # 0870112, Carlsbad, CA)+2% human
AB serum (Valley Biomedical, Cat # HP1022, Winchester, VA)
with various levels of daclizumab. After washing, cells were
stimulated with CMV pp65 RNA-pulsed DCs (1:10, DC:Tcell) in
AIM-V+2% human AB serum supplemented with 100 U/ml IL-2
(Proleukin, Prometheus, San Diego, CA) or 10 ng/ml IL-15
(PeproTech, Cat # AF-200-15, Rocky Hill, NJ) for 14 days.
Harvested cells were washed and stimulated for 6 hours with SEB
(Sigma, Cat # S0281, St Louis, MO) or CMV peptide pool (BD
Bioscience, Cat # 551969) in AIM-V+2% human AB serum
supplemented with Brefeldin A (BD Bioscience, Cat # 347688
and CD28/CD49d (BD Bioscience, Clone L25/L293). Cells were
washed, fixed with FAC Lyse (BD Bioscience, Cat # 349202),
permeablized with Perm 2 (BD Bioscience, Cat # 347692), stained
with FastImmune CD4/CD69/CD3 (BD Bioscience, Clones
SK3/L78/SK7) or CD8/CD69/CD3 (BD Bioscience, Clones
SK1/L78/SK7)+IFNc (BD Bioscience, Clone B27), and analyzed
on BD FACS Calibur.
Antibody Titers
Patient serums were analyzed for humoral response against
EGFRvIII antigen (PEPvIII) by a flow cytometry bead assay as
previously described [76]. Briefly, PEPvIII was immobilized on
magnetic particles (Dynal M280 tosylactivated beads, Cat #
142.03, Invitrogen Corporation, Carlsbad, CA) following manu-
factures directions. Serum samples were diluted 1:100 with
PBS+0.1% Tween 20 (Sigma, Cat # P7949, St. Louis, MO)
and human anti-PEPvIII antibody was captured during 30 minute
incubation with beads. After washing away unbound material,
captured antibody was detected through the binding of a labeled
secondary anti-human polyclonal antibody (Jackson Immuno
Research, goat anti-human-PE, F(ab9)2 fragment specific for both
IgG and IgM, #109-116-127) in an additional 30 minute
incubation step. Beads were again washed to remove unbound
goat anti-human-PE before analysis and labeled beads were then
analyzed on a flow cytometer to determine their mean fluorescent
intensity (MFI). Humanized anti-EGFRvIII (L8A4) was used to
generate standard curve and Prism software was used to convert
MFI to ng/ml. To ensure specificity, separate serum samples were
pre-adsorbed with PEPvIII to block specific antibody from binding
to beads. Samples were acquired on BD FACS Calibur and
analyzed with FlowJo.
Statistical Analysis
For each patient, the average percent change in the frequency
of CD4
+Foxp3
+ regulatory T-cells between baseline (i.e. vaccine 1)
and the vaccine 2, 3 and leukapheresis time points was calculated.
These follow-up assessments occurring immediately after daclizu-
mab administration were of primary interest as the serum half-life
of daclizumab is 20 days [56] and levels will continuously decrease
over time. A two-sample t-test was used to compare daclizumab
and saline arms with respect to this measure. Similar analyses were
conducted for other immunologic measures with a focus on the
average percent change between baseline and follow-up time
points between baseline, leukapheresis, and vaccine 4. For cortisol,
TSH, and ACTH, analyses focused on the average percent change
between baseline and vaccine 4, 5, and 6. The spearman rank
correlation coefficient was used to assess the association between
the frequency regulatory T-cells and anti-PEPvIII humoral
response. All statistical analyses were conducted using SAS 9.2
(SAS Institute, Cary, NC). A two-sided significance level of 0.05
was used for statistical tests.
Supporting Information
Checklist S1 CONSORT 2010 Checklist of Information.
Checklist for the ZenapaxH Activated Peptide Immunotherapy
(ZAP IT) Clinical Trial.
(DOC)
Protocol S1 Clinical Protocol. Clinical Protocol for the
ZenapaxH Activated Peptide Immunotherapy (ZAP IT) Clinical
Trial.
(PDF)
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